Evidence map›Paper›PMID 26262583›Full record

ArticleGene therapy2016

Mesothelin-specific cell-based vaccine generates antigen-specific immunity and potent antitumor effects by combining with IL-12 immunomodulator.

M-C Chang, Y-L Chen, Y-C Chiang, T-C Chen, Y-C Tang, C-A Chen, W-Z Sun, W-F Cheng

Abstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. AAV for ovarian cancer gene therapy.Cancer gene therapy · 2025
    Review
  4. Review
  5. Review
  6. Generation of a Novel Mesothelin-Targeted OncolyticInternational journal of molecular sciences · 2021
    Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

M-C ChangDepartment of Obstetrics and Gynecology, Medicine College of Medicine, National Taiwan University, Taipei, Taiwan.
Y-L ChenDepartment of Obstetrics and Gynecology, Cathay General Hospital, Taipei, Taiwan.
Y-C ChiangDepartment of Obstetrics and Gynecology, Medicine College of Medicine, National Taiwan University, Taipei, Taiwan.
T-C ChenDepartment of Obstetrics and Gynecology, Medicine College of Medicine, National Taiwan University, Taipei, Taiwan.
Y-C TangDepartment of Obstetrics and Gynecology, Medicine College of Medicine, National Taiwan University, Taipei, Taiwan.
C-A ChenDepartment of Obstetrics and Gynecology, Medicine College of Medicine, National Taiwan University, Taipei, Taiwan.
W-Z SunDepartment of Anesthesiology, Medicine College of Medicine, National Taiwan University, Taipei, Taiwan.
W-F ChengDepartment of Obstetrics and Gynecology, Medicine College of Medicine, National Taiwan University, Taipei, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer is a gynecologic malignancy with a high mortality rate. In the present study, we developed a novel cell-based vaccine, Meso-VAX, to generate mesothelin antigen-specific immune responses and immunotherapy against ovarian cancer. Mesothelin, a secreted protein anchored at the cell membrane, has recently been identified as a potential new tumor antigen for ovarian cancer. In this study, mice vaccinated with Meso-VAX and adeno-associated virus (AAV)-IL-12 exhibited dramatic increases in the number of mesothelin-specific CD4(+) helper and CD8(+) cytotoxic T-cell precursors, higher titers of anti-mesothelin Abs and in vitro tumor killing activity, and all of these mice were tumor-free after 60 days of tumor challenge. In addition, a significant reduction in peritoneal tumors and longer survival were noted in the mice vaccinated with Meso-VAX combined with AAV-IL-12. CD4(+) helper and CD8(+) cytotoxic T lymphocytes were essential for the antitumor effect generated by Meso-VAX combined with AAV-IL-12. The post-vaccination sera of the mice vaccinated with Meso-VAX and AAV-IL-12 also showed mesothelin-specific complement-dependent cell-mediated cytotoxicity. Our results suggest that a Meso-VAX cell-based vaccine combined with AAV-IL-12 can generate antigen-specific immunological responses and antitumor effects on ovarian cancer.

Indexed as

AnimalsAntibodies, NeoplasmAntigens, NeoplasmCancer VaccinesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell Line, TumorCytotoxicity, ImmunologicDependovirusFemaleGPI-Linked ProteinsHumansImmunotherapyInterleukin-12Interleukin-2MesothelinAntibodies, NeoplasmAntigens, NeoplasmCancer VaccinesGPI-Linked ProteinsInterleukin-12Interleukin-2MesothelinMsln protein, mouse

Identifiers

PMID26262583

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.